文献速递腹部技术与安全US

声辐射力脉冲超声成像:伴或不伴抗病毒治疗的慢性乙型肝炎患者的肝硬度

Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy.
PubMed 文献 · Radiology · 2018-03-27

该回顾性队列研究纳入2012至2016年台湾某三级转诊中心559例接受系列ARFI检查的慢性乙型肝炎患者,ARFI值与FIB-4(相关系数0.55,P<.001)及FibroScan(相关系数0.69,P<.001)相关;189例未治疗组ARFI值从1.11至1.11 m/sec保持不变(时间趋势P=.911),125例治疗组从1.63降至1.37 m/sec(时间趋势P<.001),伴肝硬化者(n=51)从2.15降至1.75 m/sec(P<.001),无肝硬化者(n=74)从1.27降至1.11 m/sec(P<.001);结论认为ARFI是重要的无创肝硬度检测方法,可用于慢性乙型肝炎管理的系列测量,抗病毒治疗可显著降低肝硬度。

要点

  • ARFI值与FIB-4(相关系数0.55,P<.001)及FibroScan(相关系数0.69,P<.001)相关。
  • 未治疗组ARFI值从1.11至1.11 m/sec保持不变(时间趋势P=.911)。
  • 治疗组ARFI值从1.63降至1.37 m/sec(时间趋势P<.001),伴肝硬化者从2.15降至1.75 m/sec(P<.001),无肝硬化者从1.27降至1.11 m/sec(P<.001)。

核心结论

  • ARFI超声成像是肝硬度测量的重要临床无创检查,可用于慢性乙型肝炎管理中的系列测量;抗病毒治疗在纵向随访中显著降低肝硬度。

研究设计与样本

  • 回顾性队列研究,纳入2012至2016年台湾某三级转诊中心559例接受系列ARFI检查的慢性乙型肝炎患者,收集临床信息及无创肝硬度检测(ARFI、FIB-4、FibroScan),采用随机系数线性混合效应模型比较纵向重复测量。

诊断标准与关键数值

  • ARFI值与FIB-4相关系数=0.55(P<.001)。
  • ARFI值与FibroScan相关系数=0.69(P<.001)。
  • 未治疗组(n=189)ARFI值从1.11至1.11 m/sec,时间趋势P=.911。
  • 治疗组(n=125)ARFI值从1.63降至1.37 m/sec,时间趋势P<.001。
  • 治疗组中伴肝硬化者(n=51)ARFI值从2.15降至1.75 m/sec(P<.001),无肝硬化者(n=74)从1.27降至1.11 m/sec(P<.001)。

临床应用与阅片要点

  • ARFI可作为慢性乙型肝炎患者肝硬度测量的无创检查并用于系列测量。
  • 纵向随访中抗病毒治疗与肝硬度显著下降相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To investigate the clinical utility and longitudinal change of acoustic radiation force impulse (ARFI) ultrasonographic (US) imaging in patients with chronic hepatitis B. Materials and Methods A retrospective cohort study of patients with chronic hepatitis B who underwent serial ARFI examinations in a tertiary referral center in Taiwan between 2012 and 2016 was conducted. The clinical information and noninvasive liver stiffness measurement tests (ARFI, Fibrosis-4 index [FIB-4], and FibroScan) were collected. Serial ARFI measurements were compared in patients without antiviral therapy (nontreatment group) and during antiviral therapy (treatment group). The linear mixed-effects model with random coefficients was used to compare longitudinal repeated measurements. Results A total of 559 patients undergoing serial ARFI examinations were included. The ARFI value correlated with FIB-4 (correlation coefficient = 0.55, P < .001) and FibroScan (correlation coefficient = 0.69, P < .001) results. There were 314 patients with five or more ARFI measurements in more than 3 years of follow-up. The ARFI value remained unchanged in the nontreatment group (n = 189, from 1.11 to 1.11 m/sec, time trend P = .911). However, the ARFI value declined significantly in the treatment group (n = 125, from 1.63 to 1.37 m/sec, time trend P < .001), both in patients with cirrhosis (n = 51, from 2.15 to 1.75 m/sec, time trend P < .001) and in those without (n = 74, from 1.27 to 1.11 m/sec, time trend P < .001). Conclusion ARFI US imaging is an important clinical noninvasive test for liver stiffness measurement and can be used for serial measurements in the management of chronic hepatitis B. Antiviral therapy significantly reduces liver stiffness during longitudinal follow-up.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Su TH, Liao CH, Liu CH, et al. Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. Radiology. 2018. PMID: 29584594. doi:10.1148/radiol.2018171116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。